Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil

This publication has 20 references indexed in Scilit:

• Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation
  Arquivos de Neuro-Psiquiatria, 2023
• Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of theNURTUREstudy
  Muscle & Nerve, 2023
• Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial
  Nature Medicine, 2022
• Ontario Newborn Screening for Spinal Muscular Atrophy: The First Year
  Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2021
• Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
  JAMA Neurology, 2021
• Risdiplam: First Approval
  Drugs, 2020
• Onasemnogene Abeparvovec: First Global Approval
  Drugs, 2019
• Nusinersen in the Treatment of Spinal Muscular Atrophy
  2018
• Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
  New England Journal of Medicine, 2017
• Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens
  European Journal of Human Genetics, 2011